Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) EBITDA: 2020-2025

Historic EBITDA for Biofrontera (BFRI) over the last 5 years, with Sep 2025 value amounting to -$6.3 million.

  • Biofrontera's EBITDA fell 26.57% to -$6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year increase of 9.02%. This contributed to the annual value of -$17.2 million for FY2024, which is 24.11% up from last year.
  • Biofrontera's EBITDA amounted to -$6.3 million in Q3 2025, which was down 23.61% from -$5.1 million recorded in Q2 2025.
  • In the past 5 years, Biofrontera's EBITDA ranged from a high of -$1.7 million in Q4 2024 and a low of -$16.1 million during Q3 2021.
  • Over the past 3 years, Biofrontera's median EBITDA value was -$5.1 million (recorded in 2024), while the average stood at -$5.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 587.07% in 2021, then spiked by 77.40% in 2022.
  • Quarterly analysis of 5 years shows Biofrontera's EBITDA stood at -$1.9 million in 2021, then plummeted by 196.86% to -$5.6 million in 2022, then spiked by 30.75% to -$3.9 million in 2023, then skyrocketed by 55.71% to -$1.7 million in 2024, then fell by 26.57% to -$6.3 million in 2025.
  • Its EBITDA was -$6.3 million in Q3 2025, compared to -$5.1 million in Q2 2025 and -$4.5 million in Q1 2025.